Background-Although reverse remodeling of the left atrium (LA) has been shown after MitraClip placement in degenerative mitral regurgitation (MR), changes in LA strain and strain rate have not been evaluated in these patients or compared with surgical mitral valve repair. Methods and Results-We included 87 subjects (mean age 59.7±12.3 years) with degenerative MR enrolled in the randomized EVEREST II trial (Endovascular Valve Edge-to-Edge Repair Study II). Baseline peak positive LA strain (ε) and strain rates along with longitudinal left ventricular strain (LV ε) were compared with 12-month follow-up measures. At 12 months, all 38 mitral valve repair subjects had ≤2+ MR, and 31 of the 49 MitraClip had ≤2+ MR. Baseline LA strain and strain rate values were similar in MitraClip and mitral valve repair groups. Of the strain rate measures, only peak early diastolic strain rate was consistently decreased in all treatment arms. In patients with reduced baseline LA ε, no significant change in LA ε occurred in either the MitraClip or mitral valve repair group despite significant MR and LA volume reduction. However, in patients with normal or high baseline ε, successful MR reduction by either method resulted in return of LA ε to normative values. There was a significant correlation between LA ε, LV ε values, and change in LA ε and LV ε over time. Conclusions-Changes seen in LA ε seem to depend on baseline LA and LV function. Changes in LA ε after MR reduction may reflect a decrease in LA expansion but may also be influenced by the degree of pre-existing LA dysfunction. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT00209274.
D
egenerative mitral regurgitation (MR) is one of the most common valvular heart diseases requiring surgical intervention in the Western world. 1 Over the past decade, percutaneous devices have emerged for treatment of severe MR as an alternative to surgery. MitraClip is the first approved transcatheter mitral valve repair system designed to reduce chronic, severe MR that relies on mitral valve repair via attachment of the clip on the regurgitant leaflets, imitating an Alfieri surgical repair. 2 Previous studies reported on the safety of the device implantation and the clinical benefit of the MitraClip. 3 These preliminary studies were followed by a larger trial in which surgical candidates were randomly assigned to either MitraClip or surgery. 4 Although MR reduction was more robust in the surgery arm, improvements in left ventricular (LV) function, symptoms, and quality of life have been demonstrated in the MitraClip arm. In addition, the majority of the MitraClip patients did not require reintervention after the initial procedure. 4 
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Chronic volume overload on the left atrium (LA) leads to adverse remodeling, which manifests itself as LA dilatation and LA dysfunction. 5, 6 Chronic inflammation, myocyte hypertrophy, and interstitial fibrosis have all been described on histopathology during the course of the adverse remodeling process. 7 In routine practice, LA volume is frequently used for prediction of LA dysfunction and remodeling; however, LA deformation indices are more sensitive, and impairment of LA function, as shown by these indices, can be detected at earlier stages before dilation occurs. 8 Further assessment of LA function may someday allow clinicians to select higherrisk patients and help guide appropriate treatment in a timely manner.
Although reverse LA remodeling has been shown after MitraClip therapy by using conventional echocardiography, less is known regarding the changes in LA strain and strain rate after MitraClip. 9, 10 The aim of our study was to assess the effects of MitraClip therapy on LA deformation indices assessed by speckle tracking echocardiography and compare the responses with those of surgical mitral valve repair (MVr). Left Atrial Function After MitraClip replicating the procedure. However, the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study II) randomized clinical trial data are publicly available on www.clinicaltrials.gov.
Study Population
The EVEREST II was a randomized clinical trial designed to assess the effectiveness of the MitraClip compared with mitral valve surgery in surgical candidates for severe MR. The protocol and results of the trial have been published previously. 4 We retrospectively reviewed 339 patients enrolled in the EVEREST II trial, including roll-in cases. Inclusion criteria were as follows: (1) degenerative MR treated with MitraClip or MVr, (2) available echocardiography images at baseline and follow-up, (3) sinus rhythm at the time of baseline and follow-up echocardiography, and (4) adequate echocardiographic image quality covering all LA walls.
Individuals with a paced rhythm, atrial fibrillation, functional/ ischemic MR, mitral surgery with a prosthetic valve, poor image quality, and those with missing/suboptimal images were excluded. The flow chart of excluded individuals can be seen in Figure 1 . Baseline demographics of the subjects and the information regarding hypertension, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery disease, heart failure, and prior myocardial infarction were obtained. The details of the MitraClip procedure were described previously. 3, 4 All patients provided written informed consent, and the study protocol was approved by the review boards of the participating institutions.
Echocardiography
Transthoracic echocardiography was performed using a standardized protocol at each participating site. Images were obtained at baseline and at 12-month follow-up and reviewed in the independent core laboratory (UCSF, San Francisco, CA). MR severity was quantified according to American Society of Echocardiography guidelines.
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LA volume was measured using the biplane area length method; LV volumes and ejection fraction (EF) were measured using the biplane Modified Simpson method.
Speckle tracking echocardiography analysis was performed with an offline workstation (TomTec Imaging Systems 2D Cardiac Performance Analysis, Germany). Acquired 4-chamber and 2-chamber cine images were uploaded to the software. Notably, this software was designed for LV analysis, and global LA strain and strain rate curves could not be generated automatically. Therefore, the average of the 4-chamber and 2-chamber views was used. LA endocardial contours were drawn manually. The mitral valve was not included as a LA border similar to other studies that have used this method. 12, 13 The endocardial border was automatically tracked by software throughout the cardiac cycle using speckles as previously described.
14 Manual adjustments were performed when tracking was suboptimal. Longitudinal strain and strain rate curves were generated in all segments, and the average of the segments was calculated for the corresponding time points (Figure 2 ). Using these curves, LA peak positive LA strain (ε) and strain rates (peak systolic [SRp] , peak early diastolic [SRe] , and peak late diastolic [SRa]) were calculated. All parameters were measured 3 times, and the average was noted. SRp and ε represent reservoir function, SRe represents conduit function, and SRa contractile function of the LA. Left ventricular longitudinal strain (LV ε) was measured in a similar fashion using 4-chamber and 2-chamber views.
Outcome
36-Item Short Form Survey was used to assess quality of life at baseline and follow-up. 15 Both mental and physical scores were calculated. Symptoms of heart failure were evaluated by using New York Heart Association classification. During the follow-up of 12 months, adverse events of heart failure, atrial fibrillation (beyond the periprocedural period of 7 days), and cerebrovascular accidents were identified. At 12 months, MR degree graded by follow-up echocardiogram was obtained.
Statistical Analysis
The distribution of the parameters was assessed using the ShapiroWilk test. Continuous variables were expressed as mean and SD or median and interquartile range based on the distribution of the parameters. Categorical variables were expressed as frequency and percentage. Two group comparisons were performed using a χ 2 test or Fisher exact test for categorical variables; Student t test or Mann-Whitney U test for continuous variables. Measurements at 2 time points were compared with paired Student t test or Wilcoxon signed-rank test, where appropriate. One-way ANOVA was performed to compare relative change from baseline in subgroups. When an overall significance was observed, post hoc analysis was performed using Tukey test. Spearman correlation analysis was used to compare LA ε and LV ε values at baseline and 12-month follow-up and relative changes (baseline minus follow-up) in both LA ε and LV ε values over time. Statistical analysis was performed using SPSS software version 22.0 (SPSS, Inc, Chicago, IL). A P value of 0.05 was considered statistically significant.
Results
The final cohort included 87 patients (median age 60 years, 70.1% male). Of these, 49 patients underwent MitraClip placement, and 38 patients underwent MVr. Baseline characteristics of the study patients and the comparison of the study cohort with the remaining patients enrolled in EVEREST II trial (including roll-ins) are shown in Table I in the Data Supplement. Patients in the study cohort were younger and less likely to have a history of hypertension, coronary artery disease, myocardial infarction, heart failure, and chronic obstructive pulmonary disease. The proportion of the patients with poor functional status was also lower. Additionally, the study cohort tended to have higher LV EF and smaller LA compared with the overall cohort, consistent with what one might expect by focusing on just degenerative mitral valve disease. Table II in the Data Supplement provides a comparison of study patients and the eligible patients who were excluded because of missing scan, technical issues, or poor image quality. Excluded patients were older than study patients; other parameters were comparable between 2 cohorts. Table 1 summarizes the characteristics of the patients treated with MitraClip versus MVr. All parameters were comparable between MitraClip and MVr at baseline except for hypertension, which was more common in surgery group.
Baseline median LA ε was 30% in the overall cohort. Patients were classified into 2 groups on the basis of this threshold (Table 2) . Patients with baseline LA ε <30% were older and more likely to have history of heart failure, and they tended to have larger LA. The rate of significant residual MR (>2), the proportion of poor functional class, and mental or physical quality of life scores at 12 months did not differ among the groups. Although not statistically significant, during follow-up, AF (11.6% versus 2.3%), congestive heart failure (7.0% versus 2.3%), and cerebrovascular accident (7.0% versus 4.5%) tended to occur more often in patients with baseline LA ε <30%.
At 12-month follow-up, patients were grouped according to the success of the procedure (MR ≤2+ versus MR >2+) in the MitraClip therapy arm. All surgery patients had MR ≤2+ at follow-up. Changes in conventional echocardiography parameters at 12-month follow-up in subgroups are listed in Table III in the Data Supplement. The MR severity in subgroups at baseline and follow-up can be seen in Table IV in the Data Supplement. All of the volumetric parameters and LV Figure 2 . Sample case displaying left atrial deformation analysis in 4-chamber view. Longitudinal strain (A) and strain rate curves (C) were generated in all segments (B and E), and the average of the segments was calculated for the corresponding time points (the dotted lines in A and C). Using these curves, left atrial peak positive strain (B) and peak systolic strain rate (E) were calculated. D, Endocardial speckle tracking of the left atrial in 4-chamber view. Pk indicates peak longitudinal strain/strain rate. Left Atrial Function After MitraClip EF were lower at follow-up in the MVr and MitraClip subjects with MR ≤2+. In the MR >2+ group, no change was observed. In-between-group comparisons, changes in LA volume, and LV end-diastolic volume were significantly different among the 3 groups. Change in LV EF was significantly different between MVr and MitraClip groups.
Change in strain echocardiography parameters at 12-month follow-up are summarized in Table 3 . LA ε and SRp decreased modestly or did not change, and the decrease was more robust in the surgery arm. SRe decreased significantly in all groups, including those who had residual MR >2+. SRa was slightly lower in the MitraClip group with MR >2+. LV ε declined significantly in the MVr group, although no change was observed in MitraClip groups. Among patients with MitraClip, 13 patients had 0 or 1+ MR, whereas 35 patients in MVr group had 0 or 1+ MR at 12-month follow-up. In those, LV ε did not change in MitraClip patients at follow-up compared with baseline (−20.18±4.3 and −19.6±3.8; P=0.26), whereas LV ε significantly decreased in MVr group (−21.3±3.8 and −16.8±3.9; P<0.01) despite similar MR outcome.
To understand the response of patients with different baseline LA functional properties, changes in strain were evaluated in patients with low (<30%) and normal/high (≥30%) baseline ε. The responses are illustrated in Figure 3 . Follow-up LA ε did not change in patients when the baseline ε was low, even when a significant reduction in MR was achieved by either surgery or MitraClip ( Figure 3A and 3D) . LA ε continued to deteriorate further in those who did not have reduction in MR ( Figure 3G ). In patients with normal/ high (≥30%) baseline ε, there was a significant decrease in the LA ε when MR reduction was achieved. LA ε reduction was more marked in the surgery group, with a concomitant decrease in LA volume. In the MR >2+ group, response in low baseline LA ε accounted for overall reduction of the LA ε; in contrast, in the MR ≤2+ groups, response in high baseline ε accounted for overall reduction of the LA ε. In both MitraClip groups, LV ε did not change compared to baseline. In MVr patients, LV ε significantly decreased at 12 months, regardless of the baseline LA ε.
The scatter plots describing the relationship between LA ε and LV ε are displayed in Figure 4 . There was a correlation between baseline LA ε and LV ε (r=−0.28; P=0.01) and between follow-up LA ε and LV ε (r=−0.37; P<0.001). The change in LA ε (baseline LA ε−follow-up LA ε) was correlated with change in LV ε (baseline LV ε−follow-up LV ε; r=−0.24; P=0.03).
Discussion Major Findings
This is the first study to date that evaluated the effects of MitraClip on LA deformation indices in comparison to MVr in patients with degenerative MR. At 12-month follow-up, there was a significant decrease in SRe in both treatment arms. SRa slightly decreased in MR >2+ group. The change in LA ε seemed to depend on baseline ε values. After successful MR reduction, LA ε decreased significantly in patients with normal/high baseline ε and that was more marked in the MVr group. In patients with low baseline ε, no significant change was observed despite significant reduction of MR and reduction in LA volumes. Compared with baseline, LV ε significantly decreased in MVr group, regardless of the baseline LA ε. There was significant correlation between LA ε, LV ε, and the relative change in LA ε and LV ε at 12 months. Our findings suggest that the response in LA function after treatment of MR can vary depending on baseline LA function, residual MR, longitudinal LV function, and treatment modality.
Possible Mechanisms
Tissue characteristics and amount of the interstitial fibrosis are major determinants of reservoir LA function. The increase in interstitial fibrosis compromises atrial elasticity leading to impaired compliance. Cameli et al 16 examined LA tissue samples obtained at surgery; tissue fibrosis was compared with presurgical LA functional analysis. Various degrees of interstitial fibrosis and cellular degenerative changes were observed in the examined specimens. A close association between LA ε and LA myocardial fibrosis was found and among all echocardiographic parameters. LA ε detected LA fibrosis most accurately.
With normal elasticity, increased preload augments LA reservoir function. In cases of LA stiffness-impaired reservoir function-LA cannot compensate for the change in preload leading to hemodynamic failure, such as pulmonary edema. [17] [18] [19] In this cohort, in patients with preserved baseline LA function, LA ε was lower at follow-up; this was more robust in the MVr group and concomitant with the LA volume reduction. Treatment of the MR may have reduced preload and decreased LA expansion. In patients with impaired baseline LA function, no change was observed despite correction of MR and LA volume reduction, and this may reflect LA stiffness and persistent Another contributor of LA reservoir phase is LV function. 20 In the present study, we have observed that there was a close relationship between LV ε and LA ε at baseline and at follow-up. Changes in LV ε were significantly correlated with LA ε. Moreover, among all groups, LV ε and LA ε showed a significant decrease in the MVr group, suggesting that the LA function is dependent on LV longitudinal function as shown in previous studies. 21, 22 During systole and early diastole, LA expansion and shortening on longitudinal axis are primarily influenced by movement of the valvular plane, as such, LA ε may just be reflecting the longitudinal LV systolic function rather than LA intrinsic function. Ersbøll et al 23 studied LV ε, LA ε, and LA volume in 843 patients with acute myocardial infarction and evaluated the outcomes. Although LV ε and LA ε were significantly correlated, LA ε was not an independent predictor of the adverse outcomes after adjusting for LV ε.
Although our cohort demonstrated a slightly lower LV EF at 12 months in both arms regardless of the MR outcome, the decline was significant only in successful MitraClip arm and in patients with MVr. Decreased LV EF after correction of MR occurs because of a greater decrease in LV end-diastolic volume compared with LV end-systolic volume in patients with preserved baseline LV EF. 24, 25 In contrast, in patients with impaired baseline LV function, LV EF generally improves over time. 26 This cohort focused only on degenerative MR and most individuals started with normal or hyperdynamic LV EF. Significant decline of LV ε in MVr group was another interesting finding of our study. Pandis et al 27 evaluated LV deformation parameters in patients with degenerative MR who were treated with MVr. In comparison with baseline, LV EF significantly declined immediately after surgery, which was strongly correlated with LV ε, weakly correlated with circumferential LV strain, and not correlated with radial LV strain. The presence of a high baseline LV ε predicted the decline in LV EF after the surgery, suggesting 28 studied LV deformation parameters and LV EF at baseline and compared the findings at long-term follow-up in a large cohort with degenerative MR. At long-term follow-up, LV EF and LV ε declined significantly. The authors suggested that these changes might simply implicate correction of the MR and preload reduction. The results of the above studies, along with our observation, could also reflect a direct effect of the surgery on longitudinal LV function.
It is unclear whether the higher prevalence of hypertension in MVr group and changes in blood pressure may have affected our results. Increase in acute and chronic afterload adversely affects LV ε. 29, 30 As LV ε is closely associated with LA ε, one would assume that both acute and chronic afterload changes might have an impact on LA function. In our study, systolic and diastolic blood pressure measured at the time of echocardiography reflecting the acute afterload were slightly higher at baseline in MitraClip group, and there was a trend to decline in both systolic and diastolic blood pressures in MitraClip group at follow-up. Although there was no change in blood pressure measures in MVr group at follow-up compared with baseline, there was significant decline in LV and LA ε compared with MitraClip group. The prevalence of hypertensionindicating chronic afterload-was significantly higher in MVr group. However, despite the higher prevalence of hypertension in the Mvr group, values of LV ε were not different between groups (MVr versus successful MitraClip versus unsuccessful MitraClip) at baseline as per Table 3 . 30 As MVr is associated with a lesser degree of residual MR compared with MitraClip, one additional explanation for the reduction in LV and LA ε with MVr could be related to these subjects having less MR, and hence higher afterload on the LV, as more blood has to exit across the aortic valve against systemic blood pressure. The MVr group had a greater reduction in MR reduction at 1 year, with none being MR >2 (Table III in the Data Supplement). In the MitraClip group, 42% of cases had 0 or 1+ MR, and LV ε did not change among this subset, whereas there was significant reduction in LV ε in the MVr group. One might expect some reduction in LV ε post successful MitraClip with 0 or 1+ MR, if the change in ε was all dependent on afterload. Moreover, in the successful MitraClip and MVr groups, there was no change in LA ε in those with LA ε of <30 at baseline, suggesting that afterload reduction is not the only factor affecting LA ε.
At 12-month follow-up, SRe declined significantly in all groups. SRe represents mitral inflow in the early diastole, thus correlates well with LV diastolic function.
14 In our cohort, the decrease in SRe in MitraClip groups regardless of the MR improvement may be simply explained by prolonged mitral inflow because of presence of the clip. In the surgery group, however, the mechanism is unclear. The annular ring can impede mitral flow in diastole. The changes in SRe may also reflect the decrease of MR and consequent decrease in LA pressures and LA elasticity. SRa only decreased slightly in MR >2+ group, suggesting deterioration of the contractile function as a consequence of persistent MR.
LA Function After Mitral Valve Surgery and MitraClip
Dardas et al 31 evaluated LA function before and 6 months after mitral valve surgery of degenerative MR. Despite significant decrease in LA volumes, LA stroke volume remained unchanged, and LA work increased after surgery. The investigators concluded that this might imply persistent LA dysfunction. 20 Van Garsse et al 12 reported decreased LA ε after correction of the ischemic MR with MVr, suggesting decreased expansion with correction of MR. Although our results provide complementary findings to these studies, deterioration of LA function because of atriotomy after open surgery and manipulation of the atrium cannot be ruled out.
In the study by Van Garsse et al, 12 the authors found higher rate of MR at 12-month follow-up in patients with low baseline ε. In our study, there was no difference in MR at 12 months after MR treatment between patients with low and normal/high baseline ε. The difference between our findings with the findings of this study can be explained by evaluation of different types of MR. We only included patients with degenerative MR, whereas the investigators of the above study included ischemic MR, which has different pathophysiology, course, and prognosis compared with degenerative MR.
In a recent study, Toprak et al 10 evaluated LA remodeling in 25 patients with severe MR undergoing MitraClip placement. Compared with the baseline measures, LA ε improved significantly at 12 months. Although the mean LA indicates left atrium; LA ε, left atrial peak positive strain; LA SRa, left atrial peak late diastolic strain rate; LA SRe, left atrial peak early diastolic strain rate; LA SRp, left atrial peak systolic strain rate; LV ε, left ventricular peak longitudinal strain; MR, mitral regurgitation; and MVr, mitral valve surgical repair. *Significant difference between MVr vs MitraClip groups. Left Atrial Function After MitraClip age of the study group was similar to the age of our study cohort, other characteristics were different: the pathogenesis of MR was functional in 92% of the patients, mean LVEF was 28%, mean LA ε was 7.7% and 88% of the patients had New York Heart Association III/IV at baseline. Therefore, the results of our study are not comparable to the study above. The changes in deformation parameters may exhibit variation because of differences in the pathogenesis and when baseline LA and LV function is significantly impaired.
LA Deformation Indices in MR
Previous studies reported controversial results on LA function and MR. Borg et al 32 reported increased LA deformation indices in severe MR because of increased preload and enhanced atrial compliance. In contrast, Debonnaire et al 33 described lower values in severe primary MR compared with healthy subjects. Cameli et al 34 examined LA function in patients with different grades of chronic degenerative MR. In this study, LA deformation parameters were altered during the course of the chronic degenerative MR: at the early stages, ε was higher compared with controls; in advanced stages, a stepwise decrease occurred with the increasing grade of MR. In another study by Moustafa et al, 6 the mean LA ε was significantly reduced in moderate-severe degenerative MR. On the basis of those findings, the increase in LA deformation indices in mild MR patients may be derived from increase in LA compliance, whereas that seen in moderate and severe MR patients may reflect adverse remodeling and structural abnormalities. In our cohort, there was no control group; however, baseline strain and strain rates were lower than those of previously reported normal values and above than the average of the recent studies with severe MR. 6, 26 Age, additional risk factors, functional status, quantification of the LA function with different methods and software may have caused these differences. 35 In our study, patients with low baseline ε were older, had poor functional status, and more likely to have comorbid conditions such as heart failure.
LA Function and Association With Outcome in MR
Previous studies showed that LA function indicates LA remodeling better than LA enlargement. LA reservoir function was superior to LA volume to predict presence of symptoms and adverse outcome. 36 In patients undergoing surgery for severe MR, LA ε was an independent predictor of postoperative atrial fibrillation. 37 Patients with low LA ε had worse long-term survival rates after MR surgery, regardless of the baseline functional status. 25 Moreover, reservoir function was the strongest predictor of the necessity of mitral surgery. Assessment of LA function rather than LA size may provide further information for the optimum timing of surgery and predict postoperative outcome. In a recent study that evaluated LA remodeling using LA deformation measures, and outcomes after MitraClip placement, it was found that major adverse cardiac events were common in patients with preprocedural lower LA strain. 10 Of note, most of these patients had functional MR, and baseline mean LV EF was 28%. Patients who died during the periprocedural period were excluded from the study.
In our study, among the outcomes measured, the quality of life scores were tended to be lower in patients with low baseline LA ε. Residual MR did not change at follow-up. Although not statistically significant, atrial fibrillation, congestive heart failure, and cerebrovascular accident tended to occur more often in patients with low baseline LA ε. The main aim of the current study was to evaluate the changes in deformations of the LA in MitraClip recipients versus MVr; therefore, outcome measures were beyond the scope of our study. Moreover, the number of the cases was limited for an accurate time-to-event analysis.
Limitations
Retrospective analysis of the transthoracic echocardiograms was the main limitation of the current study. Optimum echocardiographic views were required to avoid LA foreshortening and for accurate delineation of the LA endocardium. The images were not obtained for the purposes of the current study; hence, we had to exclude several cases because of suboptimal images. Patients with prosthetic valves were excluded to prevent artificial shadowing; however, we did not encounter any tracking error caused by the presence of mitral ring or clip. Speckle tracking echocardiographic analysis was performed with commercial software designed for LV strain analysis, not for LA strain analysis. For that reason, we could not generate global LA strain and strain rate curves automatically. Instead, the average of the LA strain and strain rate were calculated using 4-chamber and 2-chamber views. Any systematic errors arising from manipulation of the LV package for the LA would likely affect all individuals similarly and, therefore, be less likely to change the overall results of the study. Additionally, the LV software we used has been used for LA strain in other studies for evaluating LA deformation. 12, 13 Only patients with degenerative MR were included in the present study, and our findings cannot be generalized to other MR pathogeneses. We excluded cases that were in atrial fibrillation at the time of the echocardiography, but we cannot rule out the possibility of paroxysmal atrial fibrillation, which may have affected LA deformation measurements. Finally, because of exclusion of the patients with nondegenerative MR, prosthetic valves, atrial fibrillation, and paced rhythm, the properties of the final study cohort were significantly different than that of overall subjects enrolled in the EVEREST II trial and mostly consisted of patients with less comorbidities.
Conclusions
LA SRe decreased significantly at 12-month follow-up after MitraClip or MVr. LA ε decreased only in those with normal to elevated values at baseline and did not change in those who had reduced LA ε values before MitraClip or surgery, despite a significant decrease in MR and reduction in LA size. This suggests that reduced baseline LA ε may forecast decreased LA expansion and reduced annular excursion after correction of MR or persistent LA dysfunction despite correction of MR. There was significant correlation between baseline LA ε and LV ε and changes in LA ε and LV ε after 12 months among all subjects. These findings indicate that LA deformation is also closely related to longitudinal LV function and should perhaps be considered when deciding on the timing of an appropriate intervention for degenerative MR. 
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